Real-World Evidence from the IMDC

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

UGN-102 shows promising results in treating recurrent low-grade, intermediate-risk bladder cancer, with high response rates and manageable side effects.

Interim results reveal padeliporfin VTP therapy as a promising, safe treatment for low-grade upper tract urothelial cancer, preserving kidney function.